# Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

> **NCT06183931** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 1181 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** ALXN2220
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06183931
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2027-06-07
- **Final completion:** 2027-10-05
- **Target enrollment:** 1181 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06183931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06183931, "Study of ALXN2220 Versus Placebo in Adults With ATTR-CM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06183931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*